Roger Riera

Roger Riera

Auto-generated profile, based on publicly available information

Roger Riera

Department of Biomedical Engineering, Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Eindhoven 5612AZ, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
Indra Van ZundertIndra Van Zundert
Indra Van Zundert
ESElena Spezzani
Elena Spezzani
RBRoger R. Brillas
Roger R. Brillas
LPLars Paffen
Lars Paffen
AYAngelina Yurchenko
Angelina Yurchenko
TPTania Patiño
Tania Patiño
Due to the unique spatial addressability of DNA origami, targeting ligands (e.g. aptamers or antibodies) can be specifically positioned onto the surface of the nanostructure, constituting an essential tool for studying ligand-receptor interactions at the cell surface. While the design and ligand incorporation into DNA origami nanostructures are well-established, the study of cell surface interaction dynamics is still in the explorative phase, where in depth fundamental understanding on the molecular interactions remains underexplored. This study uniquely captures real-time encounters between DNA origami and cells in-situ using single particle tracking (SPT). Here, we functionalized DNA nanorods (NRs) with antibodies or aptamers specific to the epidermal growth factor receptor (EGFR) and used them to target EGFR-overexpressing cancer cells. SPT data revealed that ligand coated NRs selectively bound to the receptors expressed in target cancer cells, while non-functionalized NRs only display negligible cell interactions. Furthermore, we explored the effect of ligand density on the DNA origami, which revealed that aptamer-decorated NRs exhibit non-linear binding characteristics, whereas this effect in antibody-decorated NRs was less pronounced. This study provides new mechanistic insights into the fundamental understanding of DNA origami behaviour at the cell interface, with unprecedented spatiotemporal resolution, aiding the rational design of ligand-targeted DNA origami for biomedical applications.

16 March 2026 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RRRoger Riera
Roger Riera
LFLaurence W. Fitzpatrick
Laurence W. Fitzpatrick
SHSimon Huet
Simon Huet
MTMarrit M.E. Tholen
Marrit M.E. Tholen
PJPerrine Jacquot
Perrine Jacquot
LALorenzo Albertazzi
Lorenzo Albertazzi

15 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMarrit M.E. Tholen
Marrit M.E. Tholen
RRRoger Riera
Roger Riera
THTijmen H.W. Hijzelaar
Tijmen H.W. Hijzelaar
HCHao Cao
Hao Cao
FCFrancesca Cortopassi
Francesca Cortopassi
LALorenzo Albertazzi
Lorenzo Albertazzi
Single-molecule imaging and tracking have revealed fundamental biological mechanisms at the molecular scale, yet their application to clinical research remains limited by technical complexity and sample preparation incompatible with patient-derived specimens. As a result, we lack information with molecular-scale resolution of clinically relevant biomarkers. Here, we develop a workflow enabling Points Accumulation in Nanoscale Topography (PAINT) combined with single-particle tracking (SPT) on clinical liquid biopsies, allowing analysis of biomarker nanoscale organization at the single-molecule level in cancer patients. Our approach features a sample preparation tailored to liquid biopsies and requires no fixation, covalent labelling, or genetic modification, making single-molecule imaging compatible with hospital clinical workflows. We demonstrate the method’s diversity by imaging liquid biopsies from blood, bone marrow aspirates, and pleural effusions across different cancer types. PAINT-SPT captures both the expression and mobility of clinically relevant membrane receptor biomarkers, revealing pronounced inter- and intra-patient heterogeneity at the molecular and cellular levels. We discover that individual patients exhibit distinct molecular mobility fingerprints that reflect biomarker interaction states and correlate with clinical diagnostic readouts. Furthermore, these fingerprints distinguish healthy from cancer cells, enabling the development of a classifier that accurately identifies cancer cells based on their single-molecule behaviour. Together, our results establish a route to investigate patient-derived clinical samples at the single-molecule level and open new opportunities to understand cancer biology and biomarker function beyond ensemble-averaged measurements.